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Abstract 
Copy number variant (CNV) syndromes are often associated with both neurocognitive 
deficits (NCDs) and congenital heart defects (CHDs). Children and adults with cardiac 
developmental defects likely to have NCDs leading to increased risk of hospitalisation and 
reduce independence. To date, the association between these two phenotypes have not 
been explored in relation to CNV syndromes. In order to address this question, we 
systematically reviewed the prevalence of CHDs in a range of CNV syndromes associated 
with NCDs. A meta-analysis showed a relationship with the size of CNV and its association 
with both NCDs and CHDs, and also inheritance pattern. To our knowledge, this is the first 
review to establish association between NCD and CHDs in CNV patients, specifically in 
relation to the severity of NCD. Importantly, we found specific types of CHDs were 
associated with severe neurocognitive deficits. Finally, we discuss the implications of these 
results for patients in the clinical setting which warrants further exploration of this association 
in order to lead improvement in the quality of patient’s life. 
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1. Introduction 
Copy number variant (CNV) syndromes are caused by rearrangements of DNA (commonly a 
deletion or duplication) in a section of a chromosome leading to disruption of a functional 
DNA segment. The amount of DNA either deleted or duplicated can vary in length, even 
within CNV syndromes, and is generally regarded as likely to be pathogenic if over 100kb in 
length[1]. Increases or decreases in the CNVs have been associated with an array of 
neurological, psychiatric and developmental phenotypes including intellectual disability[2], 
schizophrenia[3], autism[4] and ADHD[5]. The presence of environmental factors, along with 
CNVs can also lead to increase or decrease in severity of the disease phenotype[6]. There 
are currently 67 CNV syndromes associated with developmental disorders [7]. Another 
phenotype often associated with CNVs are heart defects[8, 9]. Genome wide association 
studies (GWAS) have provided evidence suggesting that CNVs are one of the significant 
contributors to increased risk for congenital heart disease in conjunction with 
neurodevelopment[10], neurodevelopmental disorders[11] and neurocognitive deficits 
(NCD)[12-14]. Approximately 14% of infants with single ventricle heart defects were reported 
to have CNVs in comparison to 4.4% of control subjects and these accompanied 
neurocognitive decline and retarded somatic growth[15]. Adults with congenital heart defects 
(CHDs) are at an increased risk of developing neuropsychiatric symptoms such as anxiety, 
depression, and impaired functioning involving language impairment, social cognitive decline 
and delayed progression to adulthood[16-18]. However, their prevalence and the likely 
mechanisms through which these developmental deficits may occur due to the presence of 
CNVs has often been limited due to the lack of longitudinal studies. Besides, there is a major 
effect of ascertainment bias in our knowledge of the natural history of these conditions. 
The vast majority of previous research has looked at the relationship between 
neurodevelopment and congenital heart defects (CHDs) from the perspective of CHD cohort 
patients. This is to be expected as CHD appears early in life and enables prospective 
studies of neurodevelopment[19]. Many factors have been put forward as to why CHDs are 
associated with neurodevelopmental problems. In the human fetus a large part of the heart 
and brain development occurs in a similar critical window and the presence of genetic 
alteration can impact the brain and heart development[20]. Key brain development features 
such as axon guidance, synapse development and cortical networks seem to be 
compromised in fetuses with CHDs during the third trimester of pregnancy, which can lead to 
disrupted neural activity[20, 21]. Studies have shown that even before corrective surgery, 
brain injury can occur as a result of CHDs[22], associated with impaired fetal blood flow[20]. 
One disputed cause is cardiac surgery in early infancy. In some cases, surgery has resulted 
in newly-acquired brain injury [23] and adverse neurodevelopmental outcomes[24, 25], 
whereas other studies have explained the differences in these outcomes by association with 
other variables such as demographic[26, 27] and genetic factors[28]. Brain imaging studies 
in school children and adolescents with CHDs show altered white matter hyperintensities, 
connectivity[29], which partially explains the possibility as to why we see poorer fine and 
gross motor function, learning difficulties and lower IQ[13, 24]. Given that CHDs are a 
lifelong condition, gaining insight into their association with 
neurodevelopmental/neurocognitive deficits is crucial as it has clinical and public health 
relevance in terms of diagnostic assessment and preventative strategies.  
To date, there has been no studies have explored the relationship between congenital heart 
defects and neurodevelopmental disorders in relation to CNV syndromes. To fill this 
knowledge gap, we performed the systematic review to explore the relationship between 
neurocognitive deficit and CHDs from the perspective of CNV syndromes. Furthermore, we 
investigate these associations in the absence of surgery, which could be a compounding 
factor. Our objective of this study is to establish the prevalence of CHDs in CNVs associated 
with NCD and specifically what types of heart defects were associated with the cognitive 
deficits in the CNV patients. Given the exploratory nature of the study, we also looked at 
genes involved in these CNVs to explore if there can be potential converging gene pathways 
between the heart and cognitive defects that can explain the co-morbidity features. 
 
 
2. Methods 
This systematic review was conducted following the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines[30]. The protocol for this 
systematic review is registered on the PROSPERO database (CRD42019139036). 
2.1 Search strategy 
A multi-database search was performed (PubMed, EMBASE, The Cochrane Library) using 
the following search terms: ‘neurodevelopmental delay; ‘congenital heart defect’; and ‘copy 
number variant’. Articles published in the English language between January 1st 1999 and 
April 30th 2019, were extracted between 20th March and 30th April 2019 (table S1). Studies 
were extracted from the systematic literature search and selected based on their suitability, 
following the inclusion and exclusion criteria (figure 1). Inclusion criteria included the 
following: (i) Original CNV patient cohorts; (ii) CNV deletion or duplications; (iii) Patients with 
NCD and/or CHD; (iv) individual participant data is provided. Exclusion criteria included: (i) 
studies focusing on cardiac surgery and outcomes. 
2.2 Data extraction 
Individual participant data were extracted from each study. Data was either provided in the 
main text or supplementary materials. Participants were excluded for: additional 
chromosomal abnormalities; surgery before cognitive deficit could be diagnosed; patients 
described previously; prenatal patients; died before NCD was evident/could be tested. From 
all included studies, data were extracted for relevant demographics including age and 
gender of patients. Further, clinical data were extracted for purposes of quantitative 
comparison: presence of neurocognitive deficit (measured by intellectual disability, mental 
delay, mental retardation, learning difficulties, developmental delay, language deficit) and 
severity; presence of congenital heart defect; size of CNV (Mb). 
2.3 .Gene-pathway analysis 
Gene-pathway analysis was undertaken to look at any potential converging pathways that 
implicated both the brain and heart development and functionality. To ensure a 
comprehensive list of genes, CNVs included in this study and additional CNVs associated 
with neurocognitive deficit and heart defects reported in[31] were included. Genes 
associated with the CNVs were acquired from the Decipher database[7] for 1p36, 1q21.1, 
Wolf-Hirschhorn syndrome (WHS), 5p15.2 (Cri du Chat), 7q11.23, 8p23.1, 9q, 16p13.11, 
17p11.2 (Potocki-Lupski syndrome /Smith-Magenis Syndrome), 17q21.31 (Koolen de Vries 
syndrome), 22q11.2 and Xq28 syndromes. For 2q22-q23 (Mowat-Wilson) syndrome, the 
genes were acquired through NCBI RefSeq[32]. All genes were included if they were protein 
coding and reported in the OMIM database[33]. Genes were included in the pathway 
analysis if they had previously been implicated in the brain or heart (according to OMIM) or if 
they had biased or ubiquitous expression in the brain or heart according to NCBI RefSeq. 
The gene list was imported into the Reactome database[34] (version 69) and pathway 
analysis was performed utilising the ‘analyse data’ tool[35]. 
2.4 Data and statistical analysis 
A meta-analysis was conducted on all included studies using IBM SPSS Statistics Version 
25. Subgroup analysis was performed on deletion and duplications. Student’s t-tests were 
performed to explore the association between CNV size and clinical variables, chi-square 
tests and a one-way ANOVA were used to look at the association between NCD and CHD, 
along with CNV size and severity of NCD. Data is presented as mean (M) and standard error 
of the mean (SEM). Risk of bias in individual studies was assessed using the Quality In 
Prognosis Studies (QUIPS) tool[33, 36] (table S2). 
 
3. Results 
3.1 Overview of studies included 
In total, 16 studies were included in this review, looking at 12 CNV syndromes (table 1). All 
studies provided data on patients with CNVs and no control patients were looked at. All 
studies reported on neurocognitive deficit and CHD. The severity of NCD was reported in 10 
studies. Neurodevelopmental disorders were reported by 12 studies. A total of 11 studies 
reported on CNV length. All except two studies reported on the gender of patients. 
Neurocognitive deficits were very common among the studies of CNVs, ranging from 40% to 
100%; with the majority of studies showing an incidence of neurocognitive deficits towards 
the upper end of that range. The incidences are shown in figure 2. The incidence of heart 
defects had a wider range from 12% to 100%. Features of the CNVs were largely 
homogeneous between studies with other common phenotypes including 
neurodevelopmental disorders such as autism and ADHD, dysmorphic facial features, brain 
anomalies (such as delayed myelination, hypoplasia of the corpus callosum, enlarged 
ventricles), skeletal anomalies, hypotonia and seizures. 
The most common category of CHDs in these patients were septal defects, including VSD 
(26%) and ASD (24%) (figure 3). 22% of patients had patent ductus arteriosus (PDA), and 
18% of patients had aortic narrowing (including aortic stenosis and aortic coarctation). Heart 
defects that occurred in only one or two patients were classed as ‘other’, which included 
tetralogy of Fallot, pulmonary atresia, transposition of great vessels, and Ebstein’s anomaly. 
All patients with PDA and ASD had cognitive deficits, and with the exception of one patient, 
all VSD patients also had cognitive deficits. 
 
 
 
3.2 Meta-analysis 
3.2.1 Patient Cohort 
All studies were included in the meta-analysis. Inclusion was made on a patient-by-patient 
basis. Patients were excluded on an individual basis using the following criteria: (i) surgery 
was performed or patients died before neurocognitive deficit could be diagnosed, (ii) patients 
had additional chromosomal abnormalities, (iii) patients had been previously reported, (iv) 
prenatal patients. 246 out of 329 patients (74.8%) from the 17 studies were included in the 
meta-analysis. Demographics are shown in table 2. 
3.2.2 CNV size 
CNV size (the amount of DNA in Mb, that is either deleted or duplicated in patients) was 
explored to see if there was an association between length and phenotype presentation. An 
independent samples t-test showed patients with NCD (n = 135, M = 3.8, SEM = 0.46) had a 
significantly larger CNV compared to patients without a NCD (n = 8, M = 1.1, SEM = 0.20), 
***p < 0.001. Additionally, we found a significant association for the patients with CHDs (n = 
64) who had larger CNV sizes (M = 5.0, SEM = 0.73) compared to patients with no heart 
defects (n = 70, M = 3.1; SEM = 0.58), *p<0.05 (figure 4A and figure 4B, respectively). 
Taken together, these results suggest that the length of the CNV increases the risk for 
developing NCD and CHD. 
We also explored CNV size and gender and found no significant difference between female 
(n = 85, M = 4.3, SEM = 0.63) and male (n = 63, M = 3.0, SEM = 0.55) patients, p = 0.110 
(figure 4C). 
To explore whether CNV length differed between CNV type, a t-test was performed. This 
showed that patients with deletions (n = 104, M = 4.8, SEM = 0.58) had on average a 
significantly larger CNV length compared to duplication patients (n = 56, M = 1.3, SEM = 
0.07), ***p < 0.001 (figure 4D). Further, we also found that de novo CNVs (n = 52, M = 4.1, 
SEM = 1.02) were on average larger than those transmitted from a parent (n = 38, M = 1.3, 
SEM = 0.09), **p<0.01. 
To explore the association between CNV size and NCD severity, a one-way ANOVA was 
performed, which showed that the larger the CNV size the more severe the NCD (***p < 
0.001). Patients with mild NCD had an average CNV size of 1.08Mb (n = 13, SEM = 0.18), 
patients with moderate NCD had a larger average CNV size of 2.64Mb (n = 19, SEM = 0.55). 
Patients with severe NCD had the largest CNV size (n = 33, M = 6.06, SEM = 0.70). A 
Tuckey’s post hoc test showed that patients with severe NCD had significantly larger CNV 
sizes compared to both mild and moderate NCD patients (***p < 0.001, and **p < 0.01, 
respectively). There was no significant difference between mild and moderate patients (p = 
0.370). 
Based on this finding, a sub-group analysis was performed looking at CNV size and clinical 
phenotypes separately in deletion and duplication patients. In deletion patients, CNV size 
was larger for both (NCD) (4.9 vs. 0.3) and CHD (5.7 vs. 4.1) patients, however this did not 
reach statistical significance (p = 0.288 and p = 0.186, respectively). Similarly, there was no 
difference between groups for duplication patients. 
3.2.3 Association between NCD and CHD 
To explore if there was a relationship between neurocognitive deficits and congenital heart 
defects a chi-square test was performed. The results showed no significant association 
between patients who had a NCD and patients who had a CHD (p = 0.096). Due to the small 
number of participants who did not have a NCD (n = 8), this relationship was further 
explored in relation to the number of CHDs. An independent samples t-test showed a 
significant difference in number of congenital heart defects and neurocognitive deficit. 
Patients with NCD were more likely to also have heart defects (M = 0.69, SD = 0.96) 
compared to those without NCD (M = 0.33, SD = 0.49) (figure 5A). Further, a one-way 
ANOVA showed a significant difference between the number of CHDs and severity of NCD 
(*p < 0.05).  A Tukey’s post hoc test showed patients with severe NCD (n = 42, M = 0.9) 
were more likely to have numerous CHDs compared to patients with moderate NCD (n = 31, 
M = 0.4) (p = 0.027) (figure 5B). No association was found for patients with mild NCD. 
For the most common CHDs a chi-square was performed to look at the association between 
NCD severity and type of CHD (table 3). Overall heart defects and functional heart problems 
were not associated with severity. However, both PDA and VSDs were significantly 
associated with the severity of NCD with 67% and 80% of patients with PDA and VSD, 
respectively, having severe cognitive deficits. ASDs were not associated with severity of 
NCDs. 
3.3 Gene-Pathway analysis 
Another aim of the current study was to investigate if the CNVs involved in NCD and CHDs 
converge on common pathways that could a factor of these co-morbid symptoms. For this, a 
total of 126 genes from the 13 CNVs were analysed to establish the gene pathways or gene 
networks. In total, 958 pathways were found. Pathways of interest, which are of significance 
to the current study, were explored further: (i) cardiac conduction; (ii) neuronal system; and 
(iii) developmental biology. The cardiac conduction pathway analysis resulted in the least 
number CNV of genes (n = 6),followed by neuronal system that involved a slightly higher 
number (n = 8) and the developmental biology pathway which had the largest number of 
genes (n = 16), most of which were implicated in axon guidance (n = 12). Our analysis did 
not result in any single converging pathway that is of significant importance to the two 
different clinical phenotypes being studied. Genes and their corresponding CNVs and 
pathways is presented in figure S1 and are described in tables S3 and S4. 
 
 
 
 
4. Discussion 
To our knowledge, this is the first meta-analysis, based on a systematic review, to establish 
an association between NCDs and CHDs; whose subjects have CNVs in common. In this 
review we found that length of copy number variation was associated with neurocognitive 
deficits, congenital heart defects, inheritance of CNV and type of CNV (deletion or 
duplication). We also found that gender was not associated with CNV size. Further, we 
showed the number of heart defects a patient had were associated with increased severity of 
neurocognitive deficit, and PDA and VSD were associated with severe cognitive deficit. 
4.1 CNV size 
A larger CNV size would generally encompass an increased number of genes, and one 
could surmise these CNVs would therefore be associated with more symptoms, and/or an 
increased number of genes associated with a phenotype and thus enhancing the severity. 
This concept is supported by [37] who showed that more genes; and larger copy number 
lengths deleted are associated with an increased risk of neurodevelopmental disorder 
(autism) and lower IQ. A CNV that is larger than 500Kb is present in only 8% of the 
population[1]. From previous studies it can be concluded that larger CNVs are benign in 
nature[38, 39] and small CNVs show increased risk towards clinically important 
disorders[40]. 
In concordance with other studies, we found that twice as many participants had deletions 
compared to duplications, which relates to wider population studies suggesting that deletions 
occur twice as much as duplications[41], although in the general population duplications are 
more common[42]. We found that the deletions identified in the patients reported were on 
average almost four times as large as in the duplications found; duplications encompassed 
around 1Mb whereas deletions averaged over 4.5Mb. One possible explanation for this is 
the mechanism through which deletions and duplications can occur. It is generally accepted 
that both involve non-allelic homologous recombination (NAHR)[43]. It has been suggested 
that deletions are caused by intrachromatidal NAHR; whereas duplications and deletions are 
caused by interchromosomal NAHR[44] or nonhomologous end-joining (NHEJ) 
mechanisms[45]. However, other studies have shown contrasting results to ours, finding 
lower copy numbers in deletions compared to duplications[46]. Furthermore, this 
interpretation suggests that duplications would be more likely to be ascertained through their 
clinical effects than deletions of the same chromosomal region, which is contrary to general 
clinical experience. 
We found no difference in copy number between males and females in this analysis. Larger 
CNVs associated with neurodevelopmental disorders have sometimes been reported in 
females[47]. In previous studies, sex differences have been found in specific CNVs, and 
some have found that males were slightly more likely than girls to have ID (1.6:1)[48]. 
However, there was a great variation of male-to-female ratio depending on the genomic 
location of the CNV, with more females diagnosed with 22q13 and more males diagnosed 
with 22q11.2. On the other hand, whilst autism is more commonly found in males in the 
general population [49, 50], females are often more likely than males to have autism in CNV 
syndromes; particularly if occurrence is de novo [51, 52]. Further, some have shown no 
difference between the occurrence of CNVs between males and females across a range of 
CNV sizes[53] and no difference in size of de novo CNVs between males and females with 
autism spectrum disorders [54]. 
4.2 Association of CHDs and neurocognitive deficits 
We found that 98% of patients with the three most common heart defects (ASD, VSD and 
PDA) also had neurocognitive deficits. Of the patients with CHD data, 94% had 
neurocognitive deficits and therefore we were not able to find a significant or meaningful 
result of the relationship of neurocognitive deficit and congenital heart defect presence. One 
problem these studies have is that there does not seem to be a common consensus for how 
to assess neurocognitive deficits. The studies used a range of terms including mental 
retardation, intellectual disability, learning disability, developmental delay etc. Further, some 
studies used formal IQ testing, whereas some did not, and other studies did not state the 
methods used. Due to the limited research of these two variables in CNVs, we were unable 
to select for this during screening. Nonetheless, we did show that the number of heart 
defects a patient had were associated with increased severity of neurocognitive deficit. 
Further, we found that both VSDs and PDA were associated with more severe 
neurocognitive deficits. Compared to other CHDs including TOF, VSDs have been 
associated with developmental abnormalities[55]. Current research on this association is 
disputed, with some finding no association between PDA and neurodevelopment[56], 
whereas others have suggested a link[57]. Overall, these findings suggest a relationship 
between neurocognitive deficits and congenital heart defects. 
4.3 Genotype-phenotype relationship 
A gene-pathway analysis found several genes associated with multiple pathways. We 
focused on pathways associated with cardiac conduction, the neuronal system and 
development, which is the focus of the current study. Of particular interest was CACNB4 
gene (L-type calcium voltage-gated channel auxiliary subunit beta 4) which emerged as the 
only gene that was common among the three pathways. This calcium-channel subunit gene 
is particularly associated with epilepsy in infancy[58]. Additionally, defects in this gene 
associated ataxia through dysfunction in Purkinje cells within the cerebellum[59]. CACNB4 is 
important for cardiac function and is associated with cardiac muscle contraction. A recent 
genome-wide association study (GWAS) of an African-American population has identified 
that this gene is involved in idiopathic cardiomyopathy[60]. Some studies have reported no 
expression of this gene in rodent heart tissue[61]. Contrastingly, other research has 
suggested genes of the L-type calcium channel (of which CACN4B is a member) are 
associated with the heart, particularly cardiogenesis and cardiac contraction[62]. Further, 
animal studies have shown expression during development in the heart[63, 64]. The reason 
for this disparity could be because the CACNB4 gene produces at least four different 
transcripts due to alternative splicing[65]. Based on the function of this gene, it is plausible to 
hypothesise that Ca2+ transport/Ca2+ mediated signaling dysfunction are very likely 
mechanisms underlying CNV mediated NCD and CHD, and further studies are necessary to 
establish this association. 
We were not able to perform a sufficient gene-pathway analysis due to the number of genes 
that have not yet been implicated in both heart and brain phenotypes; further, current 
pathways only implicate a couple of genes (e.g. LIMK1 and MYH11 in signalling by Rho 
GTPases). Table 4 reviews the current research on the roles CNV genes and their potential 
implications in neurodevelopmental and congenital heart defects. CNVs involve a dosage 
effect whereby genes differ in expression depending on the type of CNV (deletion or 
duplication)[66-68] and there is a general difference in expression levels in the brain and 
heart. Further, genes may play different roles in both the central nervous system and the 
heart. More research needs to be conducted on genes associated with disease, in regards to 
neurological and cardiac phenotypes to allow analysis of converging pathways in CNVs that 
implicate both the brain and heart. This would then enable improved disease management 
and treatment which can be optimised and targeted as a whole rather than two separate 
clinical manifestations. 
4.4 Strengths and limitations 
The results of our systematic review/meta-analysis should be considered in the light of its 
strengths and limitations. As for the strengths, we pre-registered the protocol in a publicly 
available repository (PROSPERO), as to reduce the risk of multiple reporting. Further, we 
were able to establish the association between neurocognitive deficits and congenital heart 
defects among patients with CNVs. Additionally, we were able to show CNV size is 
implicated in both of these phenotypes and strongly suggests gene-dosage effect. There is 
limited research conducted on this association in CNVs; nonetheless, we were able to 
identify the gaps/disadvantages in patient care which has not been reported before. 
We could not assess direct association between presence of NCD and CHD due to the high 
number of patients with NCD. There is a possibility of variability in the quality of studies 
included in the current meta-analysis. Nevertheless, this did mean we could accurately 
assess the prevalence of CHDs in patients with NCD. Our results may not be valid for the 
whole CNV population because most studies were conducted with a selective and 
sometimes limited number population. However, a number the most common CNVs[69] 
were included (7q11.23, 17q21.31, 22q11.2). We could not find any converging gene 
pathways that were comorbid with both clinical presentations. Firstly, because each CNV 
could have very distinct pathways. Secondly, gene expression is more commonly reported in 
adulthood, which makes it challenging to determine its role during early development in the 
heart and brain. Thirdly, it is likely that CNV deletion and duplication of multiple genes 
activate or deactivate a specific subset of novel genes that contributes towards 
pathogenesis. 
Large multicenter studies are needed to determine the associations between neurocognitive 
deficits and CHDs which can also be used to establish the quality-of-life in patients. 
4.5 Clinical implications 
In this review, we have shown that congenital heart defects and neurocognitive defects are 
comorbid disease phenotypes in CNVs; and this knowledge has important implications for 
management of these syndromes. From the studies included, patients were generally 
referred for cytogenetic testing for neurological defects. Patients are also commonly referred 
for complex congenital heart defects. After testing; often by FISH or CGH, patients are 
diagnosed, for example, with the 22q CNV, and undergo disease phenotyping; commonly by 
the referring clinician. 
Perinatal counselling for congenital heart disease is generally determined by the success of 
surgical intervention and secondarily by the presence of genetic association. If 
perinatologists or fetal cardiologists are unaware of the implications of CNV in a given 
cardiac pathology, maternal choice on the continuation of pregnancy would not be an 
informed decision owing to incomplete counselling[70, 71]. Children with neurocognitive 
deficits are expected to be cared for by community paediatricians, rather than neurologists, 
who would also coordinate the care of affected children between different specialists. In 
reality, such a coordination with a shared care arrangement is less likely to occur owing to 
lack of knowledge of CNVs and its influence on the whole spectrum of human physiological 
systems. Similarly, the association of CNVs and delayed development may not be 
recognised in some cases of congenital heart diseases by cardiologists and cardiac 
surgeons prior to undertaking bypass surgery which renders their prognostic estimation of 
surgical intervention incorrect[72]. Furthermore, it is possible patients are not getting the 
wholistic treatment they need. Thus, there is a pressing need to increase awareness among 
clinicians of the importance of CNVs and their influence on the aetiology and neurological 
outcomes of congenital heart defects[31]. 
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8. Figure legends 
 
figure 1. Flow diagram showing the study selection and exclusion process according 
to PRISMA guidelines. 
 
figure 2. Forest plot showing incidence of neurocognitive deficit. A fixed-effects model 
with freeman double arcsine proportion showing the incidence of neurocognitive deficits in 
the studies included in the meta-analysis. 
 
figure 3. Pie chart showing prevalence of CHD type. The most common heart defects 
were septal defects followed by PDA in the studies included in the review. 
 
figure 4. The association of the CNV size on the neurocognitive deficits and 
congenital heart defects. A) Bar charts showing a significant difference between patients 
with and without NCD. B) Patients with CHD have larger CNV sizes compared to patients 
without CHD. C) Duplication patients have a significantly larger CNV size compared to 
duplication patients. D) Females and males do not have significantly different CNV lengths 
on average. Error bars represent SEM. *** p < 0.001, ** p < 0.01, * p < 0.05. 
 
figure 5. Bar graphs showing the association of average number of congenital heart 
defects and severity of neurocognitive deficit. A) In CHD patients, increasing number of 
congenital heart defects is associated with severity of neurocognitive deficit. B) A one-way 
ANOVA looking at severity of neurocognitive deficit and average number of CHDs. Error 
bars represents SEM. * p < 0.05. 
 
 
 
9. Tables 
 
Table 1. Overview of studies included in review 
CNV 
syndrome 
Patients 
(n) 
NCD
a (%) 
CHD 
(%) 
Other clinical symptoms Ref. Genes associated 
with 
neurodevelopment 
or heart 
development 
1p36 33 94 67 Poor social interaction, self-injury, 
microcephaly, brain abnormalities 
including myelination delay and enlarged 
ventricles, craniofacial features, skeletal 
defects,  urogenital abnormalities, 
hypotonia, epilepsy, eye problems, hearing 
problems 
[73] CASZ1, GABRD, 
GNB1, KCNAB2, 
KLHL17, MTHFR, 
PLCH2, PRDM16, 
RERE, RNF207, SKI, 
SLC45A1 
1q21.1 34 82 27 Autism, ADHD,  aggressive behaviour, 
microcephaly, craniofacial features, 
skeletal defects, hypotonia, seizures, 
cataracts 
[74] BCL9, GJA5, 
NOTCH2NL, PRKAB2 
Wolf-
Hirschhorn 
syndrome 
7 86 57 Craniofacial features, growth delay, 
hypotonia, epilepsy 
[75] FGFRL1, WHSC1 
13 100 31 Microcephaly, craniofacial features, growth 
delay, urogenital abnormalities, hypotonia, 
seizures, eye anomalies 
[76] 
7q11.23 14 86 29 ADHD, autism, autistic features, brain 
anomalies including enlarged ventricles, 
hypotonia, epilepsy 
[77] CLIP2, DNAJC30, 
ELN, GTF2I, LIMK1 
Williams-
Beuren 
syndrome 
10 90 100 Facial dysmorphisms, connective tissue 
abnormality, hypocalcaemia 
[78] 
5 40 80 Impaired social interaction, dysmorphic 
facial features, epilepsy 
[79] 
9qter 8 100 25 Behavioural problems including 
hyperactivity, microcephaly, brain 
anomalies, craniofacial features, 
hypotonia, seizures,   infections, eye 
problems 
[80] EHMT1, ZNF589 
15q13 17 94 12 Poor attention, aggressive behaviour, 
autistic features, brain anomalies including 
enlarged ventricles, craniofacial features, 
skeletal features, hypotonia, eye problems 
(strabismus) 
[81] CHRNA7, OTUD7A 
16p13.11 33 61 12 ASD, craniofacial features, brain 
anomalies including delayed myelination, 
hypotonia, seizures 
[82] MYH11, NDE1, 
NOMO1, NOMO3 
17q21.31 9 100 33 Hypotonia, dysmorphic facial features, 
epilepsy, skeletal deformities, urologic 
anomalies, brain anomalies 
[83] CRHR1, KANSL1, 
MAPT 
 
27 85 33 Behavioural problems, brain anomalies 
including enlarged ventricles, craniofacial 
features,  growth deficiency, skeletal 
anomalies, renal anomalies, hypotonia, 
seizures, hearing impairment 
[84] 
11 100 55 Brain anomalies, facial dysmorphisms, 
skeletal anomalies, urological defects, 
[85] 
 
aNCD includes mental retardation/delay, intellectual/learning disability, 
developmental delay and language delay 
CNV; copy number variant, NCD; neurocognitive deficit, CHD; congenital heart 
defect, ADHD; attention deficit hyperactivity disorder, ASD; autism spectrum disorder 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
hypotonia, seizures, hearing loss 
17q23.1q2
3.2 
7 100 71 Behaviour abnormalities, microcephaly, 
dysmorphic facial features, skeletal 
anomalies, hearing loss 
[86] TBX4 
22q11.2 11 64 73 Dysmorphic facial features, recurrent infect 
ions, skeletal abnormalities, renal 
abnormalities 
[87] ARVCF, CLTCL1, 
COMT, CRKL, 
DGCR6L, DGCR8, 
GSC2, LZTR1, PI4KA, 
RTN4R, SEPT5, 
SLC25A1, TANGO2, 
TBX1, TXNRD2, 
UFD1L 
Xq28 13 100 15 Autistic features, brain anomalies, 
craniofacial features, gastrointestinal 
problems, infections, hypotonia, seizures 
[88] GDI1, RPL10, TAZ 
  Table 2. Demographics of participants included in the meta-analysis 
Demographics % (n) 
CNV syndrome  
1q21.1 13.5 (34) 
1p36 13.1 (33) 
Wolf-Hirschhorn syndrome 7.9 (20) 
7q11.21 5.6 (14) 
WBS 6.0 (15) 
9qtel 3.2 (8) 
15q13 6.7 (17) 
16p13.11 13.1 (33) 
17q21.31 18.7 (47) 
22q11.2 2.8 (11) 
Xq28 5.2 (13) 
Type of CNV  
Deletion 71.8 (181) 
Duplication 28.2 (71) 
CNV Inheritance pattern  
De novo 29.4 (74) 
Inherited 24.6 (62) 
Unknown 46.0 (116) 
Size of deletion (mb), mean (SD) / range 3.55 (5.07) / 0.15 – 
31.00 
Age, mean (SD) / range 6.50 (6.39) / 0-44 
Gender  
Female 44.0 (111) 
Male 37.7 (95) 
Unknown 18.3 (46) 
Neurocognitive deficit  
Yes 85.3 (216) 
No 6.0 (15) 
Unknown 8.7 (22) 
Neurodevelopmental disorder  
Yes 19.8 (55) 
No 37.3 (94) 
Unknown 42.9 (108) 
Congenital heart defect  
Yes 38.9 (98) 
No 48.0 (121) 
Unknown 13.1 (33) 
 
 
 
Table 3. Association of severity of neurocognitive deficit and types of CHD 
 NCD, % (n) Χ2 p 
CHD type Mild Moderate Severe   
CHD 37 (11) 28  (9) 52 (22) 4.681 0.096 
PDA 7 (1) 27 (4) 67 (10) 6.083 0.048 
ASD   25 (3) 33 (4) 42 (5) 0.104 0.949 
VSD 13 (2) 7 (1) 80 (12) 11.583 0.003 
Functional 0 (0) 50 (3) 50 (3) 2.748 0.253 
NCD; neurocognitive deficit, CHD; congenital heart defect, PDA; patent ductus 
arteriosus, ASD; atrial septal defect, VSD; ventral septal defect 
 
 
Table 4. Potential role of CNV genes in neurodevelopmental and heart defects 
CNV 
syndrome 
 
Gene Pathway Gene 
expressiona 
(TPM) 
Potential role 
   Brain Heart  
1p36 CASZ1 N/A 0.7 5.7 This gene shows that significant problems/defects can occur even at low 
expression. CASZ1 had been implicated in both brain and heart 
development, with animal models showing knockouts of this gene cause 
reduced proliferation of cardiomyocytes and ventral septal defect, and is 
implicated in neurogenesis[89]. 
RERE Apoptosis 26.6 39.8 RERE has been implicated in many organs[90] and is highly expressed in 
the brain and heart. RERE has been implicated in many roles including  
cerebellar development[91], and heart tube looping[92]. 
SKI Signal transduction > signalling by 
TGF-beta > BMP / transcriptional 
activity of SMAD2/SMAD3:SMAD4 
heterotrimer 
28.7 10.4 SKI is highly expressed in the ascending aorta during development and is 
thought necessary for efficient regulation of TGF-β signalling during 
cardiac development[93].  Further, SKI knockdown has been associated 
with reduced proliferation of active astrocytes, potentially through the Ras-
Raf-ERK1/2 signalling pathway[94]. 
1q21.1 GJA5 Vesicle-mediated transport > gap 
junction trafficking and regulation 
1.7 23.2 GJA5, also known as connexin 40, is a gap junction protein associated 
with tetralogy of Fallot[95] and atrial fibrillation[96]. Gap junctions have 
long been associated with both brain[97] and heart[98]. 
WHS WHSC
1 
DNA repair > DNA double-strand break 
response 
Chromatin organisation 
35.5 10.5 Mice with reduced levels of this gene have congenital heart defects; 
including septal defects[99]. WHSC1 has been implicated in DNA damage 
and repair[100, 101].  
7q11.23 / 
Williams 
Syndrome 
LIMK1 Signal transduction > RHO GTPases 
activate PAKs/ROCKs 
Axon guidance > semaphoring 
interactions/EPH-Ephrin signalling 
39.5 4.1 LIMK1 is part of a pathway that signals through PAKs/ROCK, of which 
16p13.11 associated gene (MYH11) is also a member. Whilst more highly 
expressed in the brain, LIMK1 has been implicated in both the brain and 
heart.  Increased expression of this gene has been associated with atrial 
fibrillation[102] and impaired neuronal migration[103]. 
9qter EHMT1 Cellular response to external stimuli 
Chromatin organisation 
Gene expression > transcriptional 
19.6 8.9 Haploinsufficiency of this gene is the major cause of Kleefstra syndrome  
and 9q34 deletion syndrome[104] and is associated with both severe 
mental retardation and cardiac anomalies[105]. 
aAccording to The Human Protein Atlas[118] 
TPM; transcript per million
regulation by E2F6 
16p13.11 MYH11 Signal transduction >  RHO GTPases 
activate PAKs/ROCKs/CIT 
Axon guidance > semaphoring 
interactions/EPH-Ephrin signalling 
Smooth muscle contraction 
5.6 23.5 MYH11 is a smooth muscle gene. Smooth muscle cells have been shown 
to be essential for the formation of the ductus arteriosus during 
development[106]. Defects in this gene have been associated with been 
associated with patent ductus arteriosus[107] and thoracic aortic 
dissection[108]. 
17q21.31 KANSL
1 
Chromatin organisation 10.2 3.4 A heterozygous mutation in KANSL1 is sufficient to cause Koolen-De Vries 
syndrome; associated with intellectual disability and heart defects[109]. 
17q23.1q23.2 TBX2 N/A 2.6 4.4 TBX2 encodes a transcription factor which has many roles in early 
development including the heart and brain. This gene is particularly 
implicated in the development of the atrioventricular canal[110, 111] and 
the early anterior forebrain region[112]. 
22q11.2 CLTCL
1 
Axon guidance > semaphoring 
interactions/EPH-Ephrin signalling 
Vesicle-mediated transport > gap 
junction trafficking and regulation 
3 5.5 CLTCL1 encodes the protein CHC22 which has been shown to be 
upregulated in the brain during development[113]. This gene has been 
implicated in muscle repair[114], however a cardiac function has yet to be 
discovered. 
Xq28 RPL10 Metabolism of proteins > eukaryotic 
translation initiation/elongation 
Metabolism of RNA/amino acids 
Axon guidance > signalling by ROBO 
receptors 
989 1561.9 RPL10 encodes a ribosomal protein that has been largely implicated in 
intellectual disability[115, 116] and has also been associated with 
pulmonary stenosis[117]. 
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11. Supplementary materials 
Table S1. Example of systematic search 
Database Concept Concept input Combined with filters 
Pub med 
1 ((((((((((((Congenital heart disease*) OR Congenital heart 
defect*) OR Congenital heart anomal*) OR Congenital heart 
disorder*) OR Heart disease*) OR Heart defect*) OR Heart 
anomal*) OR Heart disorder*) OR Cardiac*) OR Cardiac 
defect*) OR Cardiac anomal*) OR Cardiac disease*) OR 
Cardiac disorder* 
Publication dates: From 
1999/01/01 to 
2019/04/30 
  
Languages: English 
2 (((Neurodevelopmental disorder*) OR Neurodevelopmental 
delay*) OR Developmental delay*) OR Intellectual disabilit* 
3 Search ((((((CNV*) OR Copy number variant*) OR 
Chromosom*) OR Chromosom* defect*) OR Chromosom* 
anomal*) OR Chromosom* disorder*) OR Chromosom* 
abnormal* 
EMBASE 1 All key words in concept 1 entered in separately and selected 
OR for all 
Publication year: from 
1999 to current 
  
Language: English 
Article type: do not 
include conference 
abstracts 
2 All key words in concept 2 entered in separately and selected 
OR for all 
3 All key words in concept 3 entered in separately and selected 
OR for all 
Cochrane 
Library 
1 (Congenital heart disease*):ti,ab,kw OR (Congenital heart 
defect*):ti,ab,kw OR (Congenital heart anomal*):ti,ab,kw OR 
(Congenital heart disorder*):ti,ab,kw OR (heart 
disease*):ti,ab,kw OR (heart defect*):ti,ab,kw OR (heart 
anomal*):ti,ab,kw OR (Heart disorder*):ti,ab,kw OR 
(Cardiac*):ti,ab,kw OR (Cardiac defect*):ti,ab,kw OR (Cardiac 
anomal*):ti,ab,kw OR (Cardiac disease*):ti,ab,kw OR (Cardiac 
disorder*):ti,ab,kw 
From 1999 to 2019 
  
All articles in the English 
language 
2 (Neurodevelopmental disorder*):ti,ab,kw OR 
(Neurodevelopmental delay*):ti,ab,kw OR (Developmental 
delay*):ti,ab,kw OR (Intellectual disabilit*):ti,ab,kw 
3 (CNV*):ti,ab,kw OR (Copy number variant*):ti,ab,kw OR 
(Chromosom*):ti,ab,kw OR (Chromosom* defect*):ti,ab,kw OR 
(Chromosom* anomal*):ti,ab,kw OR (Chromosom* 
disorder*):ti,ab,kw OR (Chromosom* abnormal*):ti,ab,kw 
 
 
Table S2. Table showing bias of each study based on the QUIPS tool 
Study Study 
Participation 
Study 
Attrition     
Prognostic 
Factor 
Measurement 
Outcome 
Measurement 
Study 
Confounding 
Statistical 
Analysis 
and 
Reporting 
Mefford et 
al. (2008) 
      
Shimada 
et al. 
(2015) 
      
Yang et al. 
(2016) 
      
Wieczorek 
et al. 
(2000) 
      
Van der 
Aa et al. 
(2009) 
      
Ghaffari et 
al. (2018) 
      
Li et al. 
(2016) 
      
Stewart et 
al. (2004) 
      
van Bon et 
al. (2009) 
      
Allach et 
al. (2018) 
      
Koolen et 
al. (2008) 
      
Zollino et 
al. (2015) 
      
Tan et al. 
(2009) 
      
Ballif et al. 
(2010) 
      
Brunet et 
al. (2006) 
      
Yi et al. 
(2016) 
      
 
 
 
 
Low bias 
Moderate bias 
High bias 
Table S3. Genes involved in cardiac, neuronal and developmental pathways 
Pathway Genes CNV 
Cardiac conduction 
YAP1- and WWTR1 (TAZ)-stimulated gene 
expression 
NPPA 
GATA4 
1p36 
8p23.1 
LTCC heteropentamer (open) transports Ca2+ 
from extracellular region to cytosol 
CACNB4 2q22-q23 
Signalling by Hippo 
Transcriptional activity of 
SMAD2/SMAD3:SMAD4 heterotrimer 
TAZ Xq28 
L1CAM interactions SCN1A 2q22-q23 
Unknown NPPB 1p36 
Neuronal system  
Potassium channels GNB1 1p36 
Transmission across chemical synapses GNB1 
CACNB4 
COMT 
PRKAB2 
1p36 
2q22-q23 
22q11.2 
1q21.1 
Neurotransmitter clearance COMT 
SLC6A3 
22q11.2 
5p15.2 
Neurotransmitter receptors and postsynaptic 
signal transmission 
PRKAB2 
ADCY2 
SLC6A3 
1q21.1 
5p15.2 
5p15.2 
Neurotransmitter uptake and metabolism in glial 
cells 
MAPT 17q21.31 
Neurotransmitter release cycle STX1A 7q11.23 
Developmental biology  
Axon guidance CACNB4 
MAPT 
SCN1A 
PLXNA3 
MYH11 
RPL10 
LIMK1 
MAPK7 
CLTCL1 
SEMA5A 
AGRN 
SCN1A 
2q22-q23 
17q21.31 
2q22-q23 
Xq28 
16p13.11 
Xq28 
7q11.23 
17p11.2 
22q11.2 
5p15.2 
1p36 
2q22-q23 
NCAM signalling for neurite outgrowth CACNB4 2q22-q23 
Activation of HOX genes during differentiation PRKAB2 
GATA4 
1q21.1 
8p23.1 
Transcriptional regulation of pluripotent stem PRKAB2 1q21.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
cells 
Regulation of beta-cell development MAPT 
GATA4 
17q21.31 
8p23.1 
LGI-ADAM interactions STX1A 7q11.23 
Transcriptional regulation of adipocyte 
differentiation 
STX1A 
GATA4 
MED9 
7q11.23 
8p23.1 
17p11.2 
Transcriptional regulation of granulopoiesis GATA4 
TAZ 
8p23.1 
Xq28 
Myogenesis TAZ Xq28 
Table S4. Brain and heart expression of genes involved in cardiac, neuronal and 
developmental pathways 
Genes Pathway Gene expression (TPM) 
  Brain 
(Cerebral 
cortex) 
Heart 
GNB1 Neuronal system 447.4 79.5 
COMT Neuronal system 109.8 51.3 
SLC6A3 Neuronal system 0 0 
ADCY2 Neuronal system 57.2 0 
NPPA Cardiac conduction 16.9 24003.4 
NPPB Cardiac conduction 0 3255.2 
PLXNA
3 
Developmental biology (axon 
guidance) 
4.1 1.9 
MYH11 Developmental biology (axon 
guidance) 
5.6 23.5 
RPL10 Developmental biology (axon 
guidance) 
989 1561.9 
LIMK1 Developmental biology (axon 
guidance) 
39.5 4.1 
MAPK7 Developmental biology (axon 
guidance) 
3.8 2.1 
CLTCL1 Developmental biology (axon 
guidance) 
3 5.5 
SEMA5
A 
Developmental biology (axon 
guidance) 
14.5 6.1 
AGRN Developmental biology (axon 
guidance) 
33.2 3.5 
MED9 Developmental biology 17.9 14.8 
PRKAB
2 
Neuronal system 
Developmental biology 
22.6 16.6 
STX1A Neuronal system 
Developmental biology 
166.6 0.5 
MAPT Neuronal system 
Developmental biology (axon 
guidance) 
116.2 2.5 
TAZ Cardiac conduction 
Developmental biology 
7.1 13.3 
GATA4 Cardiac conduction 
Developmental biology (axon 
guidance) 
0 59 
SCN1A Cardiac conduction 
Developmental biology (axon 
guidance) 
10.3 0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CACNB
4 
Cardiac conduction 
Neuronal system 
Developmental biology (axon 
guidance) 
25.9 0.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1. Venn diagram showing overlap of genes in pathways. Many genes from 
the CNVs are associated with two or more pathways involved in neuronal and 
cardiac development/function. CACNB4 is associated with all three pathways. 
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